CYP26A1 monoclonal antibody, Unconjugated, Rabbit

Artikelnummer: BWT-BS65519
Artikelname: CYP26A1 monoclonal antibody, Unconjugated, Rabbit
Artikelnummer: BWT-BS65519
Hersteller Artikelnummer: BS65519
Alternativnummer: BWT-BS65519-50UL,BWT-BS65519-100UL
Hersteller: Bioworld Technology
Wirt: Rabbit
Kategorie: Antikörper
Applikation: WB
Spezies Reaktivität: Human
Immunogen: Recombinant human CYP26A1:200-400/497
Konjugation: Unconjugated
Alternative Synonym: CP26, CP26A_HUMAN, CYP26, CYP26A 1, cyp26a1, Cytochrome P450 26A1, Cytochrome P450 family 26 subfamily A polypeptide 1, Cytochrome P450 retinoic acid-inactivating 1, cytochrome P450, family 26, subfamily A, polypeptide 1, cytochrome P450, subfamily XXVIA, polypeptide 1, Cytochrome P450RAI, hP450RAI, OTTHUMP00000020102, OTTHUMP00000020103, P450, P450 retinoic acid inactivating 1, P450RAI, P450RAI1, Retinoic acid 4 hydroxylase, Retinoic acid 4-hydroxylase, Retinoic acid metabolizing cytochrome, Retinoic acid-metabolizing cytochrome.
The cytochrome P450 proteins (CYPs) are monooxygenases that catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids, and other lipids. P450 enzymes are classified into subfamilies based on their sequence similarities. CYP26A1 is a major retinoic acid catabolic enzyme. CYP26A1 plays an important role in protecting tailbud tissues from inappropriate exposure to retinoic acid. CYP26A1 transcription is epigenetically regulated by nuclear retinoic acid receptor 2. Mutations in the gene encoding for CYP26A1 are associated with caudal agenesis and spina bifida, imperforate anus, agenesis of the caudal portions of the digestive and urogenital tracts, and malformed lumbosacral skeletal elements. CYP26A1 is upregulated in adenomatous polyposis coli mouse adenomas, human FAP adenomas, human sporadic colon carcinomas, and in the intestine of adenomatous polyposis coli (apcmcr) mutant zebrafish embryos.
Molekulargewicht: ~55kDa
UniProt: O43174
Reinheit: affinity purified by Protein A
Formulierung: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Application Verdünnung: WB=1:500-2000 not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user.
Anwendungsbeschreibung: CYP26A1 monoclonal Antibody detects endogenous levels of CYP26A1 protein.